Unprecedented access to novel CRISPR nucleases
Inscripta is a gene editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity. This includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) that will significantly increase the speed and efficiency of precision gene editing.
In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research